BTX-011

Evotec-Backed Breakpoint Therapeutics Nominates Breakthrough Cancer Treatment Candidate BTX-011 for Clinical Development

(IN BRIEF) Breakpoint Therapeutics GmbH, a company focused on developing drugs targeting the DNA Damage Response (DDR), has nominated its…

2 months ago